Thermo Fisher Scientific and Sanofi have announced an expansion of their strategic partnership, aimed at boosting domestic pharmaceutical manufacturing in the United States. As part of the deal, Thermo Fisher will acquire Sanofi’s sterile manufacturing facility in Ridgefield, New Jersey, with plans to increase its use to serve broader pharmaceutical and biotech industry needs.
While financial details of the transaction remain undisclosed, the agreement marks a significant step in both companies’ efforts to strengthen supply chains and meet growing demand for U.S.-based drug production. Thermo Fisher will continue producing Sanofi’s portfolio of sterile injectable therapies at the Ridgefield site, which includes a state-of-the-art fill-finish and packaging operation. Over 200 Sanofi employees at the site will join Thermo Fisher once the transaction is finalized.
“Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers,” said Marc N. Casper, chairman, president and CEO of Thermo Fisher. “We also look forward to welcoming the Ridgefield team and investing in additional capacity at the site.”
Sanofi’s global head of manufacturing and supply, Brendan O’Callaghan, emphasized the continued collaboration: “This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, support U.S. manufacturing, and enable future growth of the site.”
The Ridgefield facility will join Thermo Fisher’s broader network of sterile manufacturing sites in the U.S., which includes locations in North Carolina and Massachusetts. These facilities are key components of the company’s Accelerator™ platform, which offers comprehensive CDMO and CRO services designed to speed the development of new therapies.
The acquisition is expected to close in the second half of 2025, pending regulatory approvals. Once complete, the Ridgefield site will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services segment.